Thus we propose that since p53 determines this response, future clinical trials stratifying patients based upon TP53 status, and combining radiotherapy with inhibitors of specific metabolic pathways should be prioritised in SCCHN. Here, TP53 is linked to head and neck squamous cell carcinoma.